The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach by Patrlj, Leonardo et al.
© Hepatobiliary Surgery and Nutrition. All rights reserved. Hepatobiliary Surg Nutr 2014;3(5):324-329www.thehbsn.org
Introduction
Treatment of colorectal cancer and liver metastases are 
an extremely important clinical issue since that there are 
nearly a million newly diagnosed cases and nearly half 
of the million reported deaths worldwide (1). In large 
number of countries the incidence continue to rise (2), 
although the standardized prevention national programs of 
early detection have developed and brought to an earlier 
detection and diagnosed cases in early stage of tumor (3-5). 
In Asian countries, such as China, Japan, South Korea, and 
Singapore, a 2-4-fold increase in the incidence of colorectal 
cancer in the past few decades is experienced (6). In 
Western World the colorectal cancer is reported as the third 
the most frequent cancer and the most frequent cancer in 
population older than 75 years (7). 
Approximately 25% of newly diagnosed patients with 
colorectal cancer will have liver metastases at the time of 
diagnosis, another 25% will develop liver metastases during 
the course of the disease and two-thirds of all patients with 
liver metastases will die of them (8). The 10-year survival 
rate for patients with stage I disease is 90%, but for patients 
with inoperable stage IV disease, it is currently only 5% (9). 
For patients with liver metastases, the treatment strategy 
should be directed toward resectability (10).
The multidisciplinary therapeutic approach, consisting of 
new and more effective chemotherapeutic agents in single 
or combined therapy, an advanced role of interventional 
radiology with portal vein embolization (PVE) and tumor 
ablation and new strategies and techniques for hepatic 
resections, brought improved resectability rate of metastases 
to 20-30% of cases and has resulted in 5-year survival 
of 35-50% for selected cases (11-13). A need has been 
recognized for a new staging system that acknowledges 
the improvements in surgical techniques for resectable 
metastases and the impact of modern chemotherapy on 
rendering initially unresectable liver metastases from 
colorectal carcinoma resectable while distinguishing 
between patients with a chance for cure at presentation and 
those for whom only palliative treatment is possible (14). 
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There have been presented the predictive factors for 
survival and local recurrence (15,16). Traditionally, a 
staged approach (colorectal first) has been used in the 
management of patients with synchronous colorectal cancer 
and liver metastases. This involves the initial extirpation 
of the primary tumor. Systemic chemotherapy followed 
the operation, after which liver-directed operation was 
performed. The last 2 decades have brought an increased 
understanding of the biology of colorectal liver metastases, 
resulting in more effective targeted therapies in addition to 
decreased mortality after liver-directed operations (17,18).
The goal of this review is to focus onto the doubts 
concerning the operators all around the world in the 
context of reassuring the proper remnant liver volume and 
especially what to resect first in the cases of synchronous 
liver metastases of colorectal carcinoma. 
The preoperative imaging and planning the 
surgical resection
The R0 resection is the ultimate goal of the surgical therapy. 
However the proper indication is essential in order to achieve 
adequate result of resection. Resectability depends onto the 
multiple factors: the number and location of metastases, the 
remnant liver volume and quality of the liver tissue that is not 
infiltrated by tumor. All lesions identified at the initial imaging 
records (CT or MRI) before any therapy is performed have to 
be accounted during planning the liver resection in order to 
predict the total risk and the outcome of surgical procedure. 
It is recognized that chemotherapy can induce toxic injury 
of liver tissue, primarily steatohepatitis and sinusoidal injury. 
Non-contrast CT and MRI could be used to assess steatosis 
(19-21), but steatohepatitis cannot be diagnosed with imaging. 
Sinusoidal injury can be judged by indirect signs of portal 
hypertension, particularly spleen size (22), or by using the 
liver-specific MRI contrast agent gadoxetic acid (23). The 
essential three points that are ultimate for complete resection 
are preservation of liver vascularity, the adequate remnant 
liver volume with reference to body weight and total liver 
volume, and that the quality of the remnant liver parenchyma 
is acceptable (24). The ultrasound (US), especially contrast 
enhanced ultrasound (CEUS) presents a unique imaging 
method for intraoperative assessment of unrevealed metastases, 
and the relation between tumor and vascular and biliar 
structures (25), sometimes even significantly more sensitive 
than CT and/or MRI preoperative imaging records (26). 
For the detection of extra hepatic metastases and local 
recurrence at the site of the initial colorectal surgery, apart 
from CT the use of FDG-PET is widespread. A high quality 
CT can detect the majority of extrahepatic disease, however 
the FDG-PET may reveal additional signs of disease as high 
metabolic activity. Although some studies showed a change 
in management in 10-20% of patients according to record 
of FDG-PET (27,28), some reports lower percentage and 
even seem to be more suspicious in its cost-effective role (29), 
especially in the context of FDG-records following the 
preoperative chemotherapy which reduces its sensitivity. 
The surgical resection—what to resect first in 
synchronous metastases?
Surgical treatment of colorectal liver metastases remains 
the only treatment associated with a long survival time in 
patients with liver metastases from colorectal carcinoma, 
with a 40% survival at 5 years and almost 25% postoperative 
survival up to 10 years in specialized centers (30). The very 
important issue that the liver surgeon has to deal with is 
to proceed decide what to resect first liver or colon and/or 
when to undertake simultaneous surgical resections of both. 
The perfect solution seems to be a single stage colon and 
liver operation. The advantage of the one stage procedure 
could be less psychological stress for the patient, lower 
financial cost and shorter hospitalization time. On the other 
hand the advantages of the staged procedure are that there 
is no accumulation of the risks of liver and bowel resections 
at the same time. Neoadjuvant chemotherapy may be given 
before liver resection, and an extended hepatectomy or 
demanding bowel resection could be performed with the 
full attention of the surgical team focused on the liver or 
bowel disease, although, the key point for decision-making 
is the patient’s safety (1). According to the reported initial 
experience with simultaneous versus staged resections, a 
French multicenter study showed an operative mortality 
of 7% for simultaneous 2% for staged surgery (31), while 
in a single center US study the mortality was 12% for 
simultaneous and 4% for staged resections (32). Several 
studies reported simultaneous operations performed without 
mortality, however patients were selected by experienced 
hepatobiliary surgeons and the major hepatectomies 
were avoided in elderly patients the same as in those with 
demanding colorectal surgery (33-36). In addition, since the 
surgical mortality rate is significantly higher when surgery 
of extensive hepatic resections is combined with colorectal 
resection (37), this approach should be only performed in 
carefully selected patients.
The standard staged operative treatment recommendations 
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in the literature suggest resection of the primary tumor 
followed by chemotherapy for 3-6 months and second stage 
of surgical treatment that includes liver surgery. The problem 
with this approach lies in the fact that liver metastases 
determine survival more intensive than the primary colorectal 
tumor. Chemotherapy can sometime not be performed 
after the surgical treatment of the primary tumor, especially 
when complicated by anastomotic leak or dehiscence, which 
occurs in 6-12% of patients (38,39). In cases of advanced 
rectal cancer usually a long term of radio-chemotherapy of 
5 weeks is recommended and the second stage of operative 
treatment is planned 6-10 weeks following the neoadjuvant 
therapy. Therefore the patients do not receive a therapy of 
liver metastases for almost 15 weeks, which brings to the 
progress of liver metastatic disease (40). On the other hand 
some experimental studies have reported the rapid growth 
of metastases after removal of primary tumor (41,42). 
The underlying mechanism for those experimental results 
could be the loss of primary tumor-induced inhibition of 
angiogenesis in the metastases, which supports the founding 
of the increase of vascular density in humans after resection 
of primary tumor (43). 
The reverse surgical approach onto the surgical 
treatment of colorectal liver metastases known as “liver-first” 
approach is reported as feasible and safe procedure with 
promising results, although it brings along the risk of bowel 
obstruction following the growth of primary tumor, which 
can be avoided by Hartmanns procedure (39,44). Results 
from the Liver Met Survey, involving 13,334 patients 
from 330 centers in 58 countries who underwent surgery 
for liver metastases, reported a better survival outcome 
in patients who undergo first resection of liver metastases 
than in those who do not (45). A recent systematic review 
of studies published in 1999-2010 confirmed these results 
and revealed 5-year survival rates for patients with liver 
metastases in the range of 16-74% (median, 38%) after liver 
resection (46). 
The main idea of the “liver first” approach was to avoid 
the time loss between the operative therapy of primary 
tumor and the oncological therapy. Since the patients 
with rectal cancer often require a complex oncological 
therapy (chemotherapy, radiotherapy, and a complex pelvic 
operation), they could be the most proper candidates for 
such an approach (47). Despite liver-first patients usually 
have a greater hepatic disease burden and undergoing major 
resection more often, the reverse strategy was found safe 
and had long-term outcomes comparable to those of the 
other approaches (48).
How to achieve resectability without 
chemotherapy?
A large number of liver metastases should not be an absolute 
contraindication to surgery combined with chemotherapy 
provided that resection can be complete, with preservation 
of a functioning liver remnant of 25-30% (49). However, 
the problem is the loss of the proper functioning remnant 
volume of normal liver tissue, which presents an absolute 
contraindication for surgical resection. Advances in 
interventional radiology, particularly PVE in which the 
hypertrophy of normal liver tissue is provoked in order to 
ensure the proper remnant volume (50) and radiofrequency 
thermal ablation (RFA) widened the indications for surgical 
treatment of patients with colorectal cancer and liver 
metastases. In patients planned for major hepatectomies 
and with an otherwise normal liver, preoperative PVE is 
recommended when the ratio of the remnant liver to total 
liver volume is estimated to be less than 30%, whereas 
in patients with neoadjuvant chemotherapy this ratio is 
considered to be 40% (51,52). PVE is a safe procedure, but 
manipulation of the embolic material to the main portal 
vein or into branches that supply the future remnant liver 
remains a risk (1). RFA was initially anticipated for local 
treatment of hepatocellular carcinoma but has recently 
found application for the management of colorectal liver 
metastases, where its indications are still under doubt. 
Critical review of the results of RFA shows that it must be 
restricted in cases with a maximum of 3 lesions with the size 
of the biggest lesion less than 3 cm (53). Another limitation 
for the use of RFA in the management of colorectal liver 
metastases is the anatomic location of the lesion near big 
vessels, which increases the risk of incomplete ablation due 
to reduced heat effect that is used (54). A great indication of 
RFA is actually recurrence after resection, detected as small 
lesions, so it is possible not to interrupt chemotherapy (55).
A novel method in liver surgery that can solve the 
problem of remnant volume is the associating of liver 
partition and portal vein ligation (ALPPS) firstly reported 
3 years ago (56). In ALPPS approach, the portal vein 
ligation associated with in situ splitting is able to 
induce enormously accelerated hypertrophy (57). The 
neovascularization and persistence of interlobar perfusion 
are prevented by performing parenchymal dissection and 
complete devascularization of segment IV (56). The nearly 
total parenchymal dissection induced a median hypertrophy 
of 74%, which is markedly above the range that can be 
achieved by portal vein ligation or PVE alone (58,59).
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Conclusions
Surgical R0 resection still remains the only curative 
therapeutic tool in patients with colorectal cancer and liver 
metastases. The proper diagnostic algorithm is ultimate. 
The indications for surgical treatment are enlarged by 
the progress in neoadjuvant chemotherapy, diagnostic 
imaging, interventional radiology procedures especially the 
usage of PVE and radio frequent ablation. On the other 
hand the surgical techniques still develop producing the 
new pathways of treatment such as “liver-first approach” 
in the context of 2-stage operative therapy and ALPPS 
for the ensuring the remnant liver volume. Simultaneous 
liver and colorectal operations are feasible at carefully 
selected patients but should be avoided in cases of major 
hepatectomies, in elderly patients, and in patients with 
too complex intraoperative asset of colorectal tumor. The 
2-stage hepatectomies as well as the “liver first” approach 
seem to become the new treatment strategies that improved 
the prognosis in patients in whom an R0 resection can be 
achieved with curative intention. The multidisciplinary 
treatment therapeutic approach in patients with colorectal 
cancer and liver metastases is essential to make the proper 
treatment plan and achieve the best results.
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